Eversens SL
We develop innovative solutions based on breath analysis to help healthcare professionals enhancing patient outcomes contributing to the sustainability of the health care system. The analysis of exhaled biomarkers is a useful tool for the diagnosis, prognosis and monitoring of various respiratory diseases, among which asthma stands out. The company was created in 2015 by a world-class scientist’s team, expert in the detection of exhaled biomarkers.

We have launched our first product, evernoa BASE, which is a point-of-care (POC), portable, rapid, highly accurate and easy to use FeNO device. The FeNO is a biomarker of airway inflammation that facilitates the diagnosis and monitoring of Asthma, ACO (Asthma-COPD overlap) as well as other inflammatory diseases. Which makes evernoa BASE unique against its competitors are the no need to inhale through the device, which improves the hygiene and reduces the risk for cross-contamination, its top level performance and the ability to show results in only 5 seconds in a very easy to use way.

Aware of the limitations present in the current strategy for the management of patients with respiratory diseases, we have gone a step further focusing our R&D efforts on the development of evernoa SYSTEM, a unique solution providing a holistic approach to tackle with the problems for patients, professionals, pharmacies and health Care Systems, that will be available soon.

If you are interested in improving patient’s outcomes and want to learn more about what evernoa can offer, visit our webpage ( and do not doubt to contact us!
Join us
Spoken languages:
evernoa - FeNO device
Spoken languages:
Ane Botas
Spoken languages:

Smart Medical Fair
is intended for a 'Landscape Mode' use.
Your browser is now in a 'Portrait Mode'.

If you are using a mobile phone
please rotate your device.

If you are on a PC browser
please resize this page bigger.